Sinovac Biotech (SVA) Stock Price, News & Analysis

Company Overview

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Key Stats

• Today's Range: $6.47 to $6.47
• 50-Day Range: $6.47 to $6.47
• 52-Week Range: $5.73 to $8.75
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $644.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SVA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Sinovac Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sinovac Biotech investors own include Pfizer (PFE), Tesla (TSLA), AT&T (T), Exxon Mobil (XOM), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ).

Company Calendar

• Record date for 7/7 Dividend: 5/23/2025
• Dividend Payable: 7/07/2025
• Ex-Dividend for 7/7 Dividend: 7/08/2025
• Today: 7/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SVA
• CIK: 1084201
• Web: www.sinovac.com
• Phone: 86-10-5693-1800
• Fax: 86-10-5693-1800
• Employees: 3,261
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $448.27 million
• Price / Sales: 1.44
• Cash Flow: $0.17 per share
• Price / Cash Flow: 38.95
• Book Value: $120.83 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 99,640,000
• Free Float: 86,894,000
• Market Cap: $644.67 million
• Optionable: Optionable
• Beta: 0.01